Pediatric Hematology Hematopoietic Stem Cell Transplantation

Angels Camp, CA, United States

Pediatric Hematology Hematopoietic Stem Cell Transplantation

Angels Camp, CA, United States
SEARCH FILTERS
Time filter
Source Type

Rosenthal J.,Pediatric Hematology Hematopoietic Stem Cell Transplantation | Wong J.,City of Hope | Stein A.,Pediatric Hematology Hematopoietic Stem Cell Transplantation | Qian D.,City of Hope | And 5 more authors.
Blood | Year: 2011

This phase 1/2 study assessed the augmentation of reduced-intensity conditioning (RIC) with total marrow and lymph node irradiation (TMLI), for peripheral blood stem cell transplantation, in patients with advanced hematologic disease. The regimen consisted of fludarabine 25 mg/m2 per day for 5 days, melphalan 140 mg/m2 for one day, and TMLI radiation at 150 cGy/fraction in 8 fractions over 4 days. Eligible patients were over 50 years old and/or had compromised organ function. Median age of the 33 evaluable patients was 55.2 years. Eighteen events of nonhematologic grade III or higher toxicities occurred in 9 patients. Day 30 and day 100 mortalities were 3% and 15%, respectively. Patients achieved myeloid and platelet engraftment at a median of 14 days after transplantation. Long-term toxicities occurred in 2 patients: hypokalemia and tremor, both grade III, on days 370 and 361 after transplantation. Fourteen patients died, 7 of relapse-related causes and 7 of non-relapse-related causes. With a median follow-up for living patients of 14.7 months, 1-year overall survival, event-free survival, and non-relapse-related mortality were 75%, 65%, and 19%, respectively. Addition of TMLI to RIC is feasible and safe and could be offered to patients with advanced hematologic malignancies who might not otherwise be candidates for RIC. © 2011 by The American Society of Hematology.

Loading Pediatric Hematology Hematopoietic Stem Cell Transplantation collaborators
Loading Pediatric Hematology Hematopoietic Stem Cell Transplantation collaborators